A phase II trial of chemotherapy-free neoadjuvant camrelizumab plus apatinib for resectable HNSCC: pathological response and vascular-immune crosstalk.
PURPOSE To evaluate the efficacy, safety, and tumour microenvironment remodelling of neoadjuvant camrelizumab plus apatinib in resectable head and neck squamous cell carcinoma (HNSCC; stage II-IVA). MATERIALS AND METHODS In this single-arm, exploratory phase II trial (ChiCTR2100051989), 41 patients with resectable HN...